Alumis Inc. Common Stock (ALMS) es una empresa que cotiza en bolsa en el Salud sector, operando dentro de la Biotecnología industria. La empresa tiene su sede en South San Francisco, CA, United States. El CEO actual es Martin Babler.
ALMS tiene fecha de IPO 2021-02-22, 168 empleados a tiempo completo, cotiza en el NASDAQ Global Select, una capitalización de mercado de $2.82B.
Alumis Inc. is a clinical-stage biopharmaceutical company dedicated to developing innovative medicines for autoimmune and neuroinflammatory disorders. The company's lead candidate, ESK-001, is an allosteric tyrosine kinase 2 (TYK2) inhibitor in development for plaque psoriasis, systemic lupus erythematosus, and non-infectious uveitis. Additionally, Alumis is advancing A-005, a brain-penetrant TYK2 inhibitor designed to treat neuroinflammatory and neurodegenerative diseases. Founded in 2021 and formerly known as Esker Therapeutics, the company rebranded to Alumis Inc. in January 2022 and is headquartered in South San Francisco, California.
